1. EXECUTIVE SUMMARY
2. MARKET SNAPSHOT
2.1. Market Overview
2.2. Market Definition
2.3. Scope of the Study
2.4. Market Segmentation
3. BUSINESS LANDSCAPE
3.1. Market Drivers
3.2. Market Restraints
3.3. Market Opportunities
3.4. Porter’s Five Forces Analysis
3.5. Industry Value Chain Analysis
3.6. Policies and Regulations
3.7. Strategic Recommendations
3.8. Products in Pipeline
4. TECHNOLOGICAL OUTLOOK
5. PERSONALIZED MEDICINE MARKET BY TYPE
5.1. Introduction
5.2. Pharmacogenomics
5.3. Biomarkers
5.4. Precision Therapeutics
5.5. Others
6. PERSONALIZED MEDICINE MARKET BY APPLICATION
6.1. Introduction
6.2. Oncology
6.3. Cardiology
6.4. Infectious Disease
6.5. Neurology
6.6. Others
7. PERSONALIZED MEDICINE MARKET BY END-USER
7.1. Introduction
7.2. Hospitals & Clinics
7.3. Diagnostics Centers
7.4. Others
8. PERSONALIZED MEDICINE MARKET BY GEOGRAPHY
8.1. Introduction
8.2. North America
8.2.1. By Type
8.2.2. By Application
8.2.3. By End-User
8.2.4. By Country
8.2.4.1. USA
8.2.4.2. Canada
8.2.4.3. Mexico
8.3. South America
8.3.1. By Type
8.3.2. By Application
8.3.3. By End-User
8.3.4. By Country
8.3.4.1. Brazil
8.3.4.2. Argentina
8.3.4.3. Others
8.4. Europe
8.4.1. By Type
8.4.2. By Application
8.4.3. By End-User
8.4.4. By Country
8.4.4.1. Germany
8.4.4.2. France
8.4.4.3. United Kingdom
8.4.4.4. Spain
8.4.4.5. Italy
8.4.4.6. Others
8.5. Middle East and Africa
8.5.1. By Type
8.5.2. By Application
8.5.3. By End-User
8.5.4. By Country
8.5.4.1. Saudi Arabia
8.5.4.2. UAE
8.5.4.3. Others
8.6. Asia Pacific
8.6.1. By Type
8.6.2. By Application
8.6.3. By End-User
8.6.4. By Country
8.6.4.1. China
8.6.4.2. India
8.6.4.3. Japan
8.6.4.4. South Korea
8.6.4.5. Indonesia
8.6.4.6. Thailand
8.6.4.7. Taiwan
8.6.4.8. Others
9. COMPETITIVE ENVIRONMENT AND ANALYSIS
9.1. Major Players and Strategy Analysis
9.2. Market Share Analysis
9.3. Mergers, Acquisitions, Agreements, and Collaborations
9.4. Competitive Dashboard
10. COMPANY PROFILES
10.1. F. Hoffmann-La Roche Ltd.
10.2. Illumina, Inc.
10.3. Novartis Ag
10.4. Pfizer Inc.
10.5. Merck KgaA
10.6. Astrazeneca Plc
10.7. Bristol Myers Squibb Company
10.8. Amgen Inc.
10.9. Guardant Health Inc
10.10. Caris Life Sciences
10.11. Thermo Fisher Scientific Inc.
11. APPENDIX
11.1. Currency
11.2. Assumptions
11.3. Base and Forecast Years Timeline
11.4. Key benefits for the stakeholders
11.5. Research Methodology
11.6. Abbreviations
LIST OF FIGURES
LIST OF TABLES